Dolorex (Ketorolac)

Quick links to important sections

Dolorex (Ketorolac)

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolorex (Ketorolac)

What Type of Medicine is Ketorolac (Dolorex)?

Dolorex is a trade name for the medication containing the active ingredient Ketorolac tromethamine, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This synthetic compound is utilized for its potent analgesic effects, serving as a non-narcotic option for pain control. As an NSAID, it possesses triple therapeutic actions, functioning as an anti-inflammatory drug and an antipyretic, in addition to its primary role as a pain reliever.


Composition and Pharmaceutical Preparations

The core composition of the medication is a single-ingredient product, featuring Ketorolac tromethamine as the active entity. It is prepared in multiple dosage forms, allowing for both systemic administration and targeted local administration. These preparations include tablets for oral use, a sterile solution for intramuscular or intravenous injection, and an ophthalmic solution for topical use in the eye. The injectable solution is a key preparation that enables use for rapid, systemic pain management.


General Purpose of the Ketorolac NSAID Class

The general therapeutic purpose of Ketorolac is the short-term management of moderately severe acute pain, such as pain following surgical procedures or trauma. Its function is to reduce the body’s production of inflammatory mediators, providing relief from discomfort. It is used as an effective opioid-sparing agent in acute pain settings when strong, non-addictive relief is required.

Regulatory References

  1. Ketorolac: MedlinePlus Drug Information

What side effects are possible with Dolorex (Ketorolac)?

Possible side effects and safety information

The official safety profile for Ketorolac is characterized by potential adverse reactions typical of the Nonsteroidal Anti-inflammatory Drug (NSAID) class, as documented by regulatory agencies like the FDA and EMA. Adverse reactions are grouped by system and frequency.


System-Organ Classes and Common Adverse Reactions

Adverse effects are categorized by the anatomical system affected. Common reactions (occurring in ge 1/100 to < 1/10 users) frequently involve the Gastrointestinal and Nervous Systems. These commonly listed effects include nausea, vomiting, dyspepsia, gastrointestinal pain, headache, dizziness, and somnolence.


Serious Adverse Reactions and Regulatory Constraints

Regulatory documents explicitly highlight the potential for Serious Gastrointestinal (GI) Adverse Events, including bleeding, ulceration, and perforation, which can be fatal. The profile also notes the risk of Serious Cardiovascular (CV) Thrombotic Events, such as Myocardial Infarction (heart attack) and Stroke. Acute kidney failure and severe skin reactions are also documented.

Due to these risks, systemic treatment (oral or injectable) is officially limited to a maximum of five days or less for combined administration. The risk of serious GI and CV events increases with both dose and duration.


Population-Specific Safety Notes

The medicine is subject to safety restrictions regarding specific populations and conditions. Older adults are documented to have a higher risk of serious GI and renal adverse events. It is contraindicated in patients with advanced renal impairment, active peptic ulcer disease, and pregnant women in the third trimester.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Dolorex (ketorolac), similar to other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), primarily involves acute, but generally reversible, symptoms affecting the gastrointestinal and nervous systems. Immediate medical attention is required for any suspected overdose.

Documented Overdose Symptoms

The most common manifestations observed following an acute NSAID overdose include lethargy, drowsiness, nausea, vomiting, and pain in the upper abdomen (epigastric pain). Severe outcomes are rare but pose significant risk. These serious manifestations can include:

  • Gastrointestinal Bleeding
  • Acute Renal Failure (sudden kidney damage)
  • Hypertension (high blood pressure)
  • Respiratory Depression (slowed or shallow breathing)
  • Coma (profound unconsciousness)
  • Anaphylactoid reactions

Single overdoses of ketorolac specifically have been associated with peptic ulcers, erosive gastritis, abdominal pain, and renal dysfunction, which typically resolve upon stopping the drug.

Emergency Response

Immediate medical help must be sought if a ketorolac overdose is suspected due to the potential for life-threatening complications like acute renal failure or GI bleeding. There is no specific antidote for ketorolac overdose; therefore, management focuses on symptomatic and supportive care.

For patients presenting within four hours of ingesting a large oral overdose (typically 5 to 10 times the usual dose), medical professionals may administer activated charcoal and/or an osmotic cathartic to reduce absorption of the drug.

Therapeutic Uses of Dolorex (Ketorolac)

What Dolorex (Ketorolac) Treats: Main Uses and Benefits

The primary therapeutic use of Ketorolac is centered on short-term symptom management in contexts of heightened discomfort. It is commonly applied across domains where short-term symptomatic support is appropriate, particularly in settings involving acute or disruptive symptom patterns.

This medication is relevant for easing moderately severe pain, such as discomfort following surgical procedures or sudden physical trauma. It is also commonly used to help with symptoms related to inflammatory or irritative states and fever. Separately, localized application is relevant for easing ocular inflammation and itching linked to conditions like seasonal allergies or post-operative recovery. This non-narcotic option contributes to improved day-to-day comfort during symptomatic periods and may assist with maintaining a sense of stability when symptoms are more noticeable.

“The core purpose is providing support that helps ease the overall symptom burden, offering relief when discomfort is pronounced.”


Quick Fact: Relevant for Acute, Moderately Severe Pain

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Who can and cannot use Dolorex (Ketorolac)?

The eligibility for Ketorolac is restricted primarily to adults 16 years of age and older who require short-term management of moderately severe acute pain, with treatment duration strictly limited to five days or less. Use in pediatric patients is generally not indicated, and safety and efficacy have not been established in children under 16 years of age.

Ketorolac is contraindicated in multiple populations due to the risk of serious complications, as stated in regulatory labeling:

  • Patients with active peptic ulcer disease or a history of recent gastrointestinal bleeding or perforation.
  • Patients with advanced renal impairment or those at high risk of bleeding (including patients on anticoagulants).
  • Individuals with a history of allergic reactions (asthma, urticaria) after taking aspirin or other NSAIDs.
  • Patients with severe heart failure or severe hepatic failure.
  • It is contraindicated in women in the third trimester of pregnancy, during labor and delivery, and in breastfeeding mothers.

Older adults (65 years and older) and patients weighing less than 50 kg require reduced daily dosages and close monitoring due to an increased risk of adverse events.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Ketorolac is defined by several formal restrictions and documented pharmacokinetic and pharmacodynamic outcomes as stated in official regulatory labels.

Formal Contraindications

Co-administration is strictly prohibited with several medicinal products due to high interaction risk, including other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Aspirin, due to the cumulative risk of severe gastrointestinal effects. The combination with Anticoagulants (e.g., Warfarin) and Oxpentifylline (Pentoxifylline) is also contraindicated due to a majorly increased risk of hemorrhage. The use with Probenecid is prohibited as it significantly increases the concentration of Ketorolac in the plasma by decreasing its clearance. Co-administration with Lithium Salts is contraindicated because Ketorolac reduces Lithium's renal clearance, leading to elevated plasma levels and potential toxicity.

Documented Pharmacodynamic and Exposure Effects

Ketorolac's inhibition of prostaglandin synthesis can reduce the natriuretic and diuretic effect of Diuretics and may impair the response to ACE Inhibitors or ARBs, potentially increasing the risk of renal impairment. Similarly, co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs) may increase the risk of bleeding. For oral administration, a high-fat meal delays the time-to-peak concentration (Tmax) of Ketorolac, though the extent of absorption is not significantly affected. Interaction risks are noted as greater in elderly patients and individuals with advanced renal impairment.

Mechanism of Action

Targeting the Cyclooxygenase Enzyme System

Ketorolac functions as a non-selective competitive inhibitor of the Cyclooxygenase (COX) enzymes, targeting both the COX-1 and COX-2 isoforms. This molecular action suppresses the entire Arachidonic Acid Cascade, preventing the conversion of arachidonic acid into key mediators like prostaglandins and thromboxanes.


Modulation of Nociceptive and Central Pathways

The suppression of prostaglandin synthesis at injury sites prevents the chemical sensitization of peripheral nociceptors (pain nerves), which fundamentally decreases the excitability of peripheral nociceptors. Simultaneously, central action on prostaglandins in the hypothalamus allows for the modulation of the body's thermoregulatory set point, influencing the hypothalamic thermoregulatory set point.


Functional Constraint of Homeostatic Mechanisms

The drug's non-selective mechanism extends to blocking the constitutive COX-1 enzyme responsible for homeostatic prostaglandins. This interference affects the internal regulation of systems that rely on these mediators, such as those governing gastric mucosal integrity and regulation of renal blood flow.

Dosage and Administration Information

The use of Ketorolac is governed by strictly defined parameters, establishing precise limits on the route, quantity, and total duration of administration.

Administration Routes and Sequential Therapy

Ketorolac is approved for Intravenous (IV), Intramuscular (IM), and Oral administration in its systemic forms. The drug must be used sequentially: therapy is required to begin with the injectable form, as the oral tablet is not approved for use as an initial dose for acute pain management.

Dosing Regimens and Maximum Limits

Maximum daily doses are prescribed based on patient weight and age, or the presence of renal impairment. The combined total duration of all systemic use (IV, IM, oral, or nasal) must not exceed 5 days for any acute episode.

Dosage Parameters (Adults) Standard Adult (≥50 kg) Adjusted Populations (≥65 years, <50 kg, or Renal Impairment)
IV/IM Multiple Dose 30 mg every 6 hours 15 mg every 6 hours
Parenteral Max Daily Dose 120 mg/day 60 mg/day
Oral Continuation Dose 10 mg every 4–6 hours 10 mg every 4–6 hours
Oral Max Daily Dose 40 mg/day 40 mg/day

Procedural and Time Constraints

Procedural rules mandate that the IV bolus be administered over no less than 15 seconds, and IM injections must be given slowly and deeply. Doses are scheduled at fixed intervals (every 4 to 6 hours), which should not be shortened. The drug is explicitly contraindicated for intrathecal or epidural administration.

This protocol defines a rigid, time-bound structure for Ketorolac use, mandating the transition from initial parenteral administration to oral continuation and strictly limiting total treatment duration to ensure adherence to clinical guidelines.

Recent Clinical Evidence

Research Evidence for Acute, Moderately Severe Pain

Clinical research on Ketorolac primarily involves short-term Randomized Controlled Trials (RCTs) used to explore how symptoms of acute, moderately severe pain evolved. These studies examine outcomes related to physical discomfort in patients, such as pain following injury. Trials focus on immediate results, monitoring the time elapsed until patients reported a predefined change in their pain score following administration. Evidence is explicitly limited to very short-term use, as regulatory constraints restrict the duration of study to five days.

Overview of Studies in Postoperative Pain Management

The research base for postoperative use is extensive, consisting largely of systematic reviews and meta-analyses of RCTs in adult patients recovering from surgery. Studies explore whether Ketorolac, when used as part of a regimen, was associated with the amount of opioid pain medication requested during recovery. However, when pooling data, findings often show considerable variability (heterogeneity) across different surgical types, meaning subgroup findings are uncertain in certain clinical contexts.

Research in Specialized and Pediatric Pain Settings

Research has evaluated Ketorolac in specialized settings, including non-inferiority trials for acute migraine headaches and studies involving children and adolescents. While research provides insight into short-term changes in symptoms in these groups, the evidence base is less mature. The use of Ketorolac in pediatric populations is not consistently studied or labeled across all regulatory regions, indicating data for these groups remain insufficient to establish a broad clinical consensus.

What Remains Uncertain in the Research Landscape

Across all indications, the follow-up durations in trials were limited, meaning long-term effects are not fully established. Data are still emerging for certain long-term observations. Furthermore, research findings apply only to the specific populations studied and do not translate universally, highlighting a consistent need for more standardized and extensive research in specific patient cohorts.

Key Studies & References

  1. Ketorolac Tromethamine Injection - FDA/DailyMed Drug Label (Prescribing Information)

Frequently Asked Questions (FAQ)

Common questions about Dolorex (Ketorolac) (FAQ)


Q: Is Dolorex the same type of drug as Ibuprofen or Naproxen?

Dolorex (Ketorolac) belongs to the same class of medicines as Ibuprofen and Naproxen, known as Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

According to regulatory documents, the use of Ketorolac is strictly prohibited with other NSAIDs or aspirin due to a significantly increased and cumulative risk of serious side effects.

Q: Can I take Dolorex if I have a history of high blood pressure?

Official labeling notes that NSAIDs, including Ketorolac, can cause the development of new high blood pressure (hypertension) or worsen existing high blood pressure.

Ketorolac may also interact with some medications used to treat hypertension. This highlights the importance of discussing this condition with a healthcare provider.

Q: Is it normal to feel dizzy after taking Dolorex?

Yes, dizziness is listed in official regulatory documents as a common adverse reaction associated with the use of Ketorolac.

Like many pain medications, Ketorolac can affect the nervous system, potentially causing dizziness or drowsiness.

Q: Are there any long-term side effects associated with Ketorolac use?

Ketorolac is approved only for short-term use, limited to a maximum of 5 days for all forms of administration.

Due to the risk of serious side effects, including gastrointestinal bleeding and heart-related events, long-term use is strictly not approved or permitted under regulatory guidelines.

Q: Can Dolorex be used for menstrual cramp pain?

The drug is primarily indicated for the short-term management of moderately severe acute pain, such as pain following surgery or trauma.

Official product information does not consistently include general menstrual cramp pain (dysmenorrhea) as a specific approved use across all regions.

Q: Does Dolorex (Ketorolac) interact with common cold or flu medications?

Regulatory information advises against taking Ketorolac with other NSAIDs or Aspirin.

Since many over-the-counter cold and flu preparations contain NSAIDs or Aspirin, combining them with Dolorex can create an increased risk of serious side effects, particularly gastrointestinal bleeding.

Q: How quickly does Dolorex begin to provide pain relief?

According to official pharmacokinetics data, for the intramuscular injection form, the concentration of the drug in the body typically peaks between 20 to 60 minutes.

The maximum pain relief effect is generally reached within 2 to 3 hours after administration.

Q: Does Dolorex cause drowsiness or make you feel sleepy?

Yes, regulatory documents list somnolence, which is a medical term for drowsiness or sleepiness, as a common adverse reaction.

Because this effect is noted in official documentation, individuals should be cautious when performing tasks that require mental alertness or operating machinery.

Q: Are there any specific foods or drinks to avoid while taking Dolorex?

Consumption of alcohol is strongly advised against while taking Ketorolac, as this combination significantly increases the risk of gastrointestinal bleeding.

Official documents also note that a high-fat meal may delay the time it takes for the drug to reach its maximum concentration in the blood.

Q: Is Dolorex considered a strong pain reliever compared to over-the-counter options?

Regulatory labeling states that Ketorolac is indicated for the management of acute pain that requires analgesia (pain relief) at the opioid level.

The indication for 'opioid level' pain management reflects its intended use for pain of greater severity than typically managed by standard over-the-counter NSAIDs.

Q: How long does the pain relief effect of Dolorex typically last?

The elimination half-life of Ketorolac, which is the time it takes for half of the drug to be cleared from the body, is generally between 4 and 6 hours.

Fixed dosing intervals are established to achieve and maintain therapeutic concentrations of the drug for pain relief.

Q: Is Dolorex safe for elderly patients?

Older adults (65 years and older) are documented in regulatory sources to be at a greater risk for serious gastrointestinal and kidney-related side effects.

This population requires reduced daily dosages and close monitoring due to increased risk of adverse events, as indicated by regulatory guidelines.

Q: What are the signs of an allergic reaction to Dolorex?

Hypersensitivity reactions can occur, ranging from mild reactions to severe anaphylactic shock.

Regulatory warnings state that signs can include hives, difficulty breathing or wheezing, and swelling of the face, mouth, throat, or tongue.

Q: Can Dolorex interact with blood thinner medications?

Yes. The use of Ketorolac is strictly contraindicated with certain blood thinners, specifically anticoagulants such as Warfarin, due to a majorly increased risk of hemorrhage (severe bleeding).

Caution is also advised when co-administering it with SSRI-type antidepressants, as this combination also increases the risk of bleeding.

Q: Do doctors ever prescribe Dolorex for chronic pain conditions?

No. Official regulatory documents strictly state that Ketorolac is NOT indicated for minor or chronic painful conditions.

It is exclusively approved for the short-term, acute management of moderately severe pain.

Q: Why do some people refer to Ketorolac as 'Toradol'?

Toradol is one of the original and common trade names (brand names) under which the active ingredient, Ketorolac tromethamine, has been marketed.

This is why people often use the brand name when referring to the medicine.

Q: What kind of research supports the use of Dolorex for post-operative pain?

Clinical trials support the use of Ketorolac in managing pain after surgery.

Studies show its effectiveness as an analgesic and confirm its ability to act as an opioid-sparing agent, meaning it can help reduce the amount of opioid medication needed during recovery.

Q: Can Dolorex cause problems with liver function?

Like other NSAIDs, Ketorolac can cause elevations in liver enzymes, which can be a sign of liver irritation, and rare, severe liver reactions have been reported.

Its use is contraindicated in patients who already have severe hepatic (liver) failure.

Q: Why is Dolorex not typically used for simple fever reduction?

Although Ketorolac has antipyretic (fever-reducing) properties, it is not indicated for minor conditions.

Due to the strictly limited duration of use and the risk of serious side effects (like GI and CV events), it is reserved only for moderately severe pain and is not appropriate for simple fever reduction.

Q: Can taking Dolorex affect the healing process of an injury?

Regulatory information notes that Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may slow or delay healing.

This warrants careful consideration, particularly in connection with surgical procedures where interference with platelet aggregation may increase bleeding time.

Q: What are common reasons a doctor would switch a patient from Dolorex to another pain reliever?

The primary reason for switching is the strict regulatory limit on treatment duration.

Official protocols mandate that the combined use of all systemic forms of Ketorolac must not exceed 5 days, requiring a transition to alternative medications for continued pain relief.

Q: What are the recommendations for taking Dolorex before or after a minor dental procedure?

Ketorolac is indicated for the short-term management of acute, moderately severe pain following procedures.

However, it is strictly contraindicated as a prophylactic analgesic (preventive painkiller) before any major surgery due to the risk of increased bleeding.

Q: How does the route of administration (oral vs. injection) change how Dolorex works?

While the total absorption of the drug is the same for the oral, intramuscular, and intravenous forms, the oral tablet is not approved as an initial dose for acute pain.

Therefore, therapy must begin with the injectable form, and the maximum approved daily dose is lower for the oral form than the injectable form.

Q: What evidence exists regarding the effectiveness of Dolorex in acute musculoskeletal injuries?

Regulatory reviews and guidelines include data on Ketorolac’s effectiveness for the short-term management of moderate to moderately severe pain.

This evidence includes pain resulting from acute musculoskeletal trauma or injuries.

Q: Are there any mental side effects like anxiety or mood changes reported with Dolorex?

Yes, official adverse reaction reports list side effects that can affect the nervous system and mental state.

These include reported events such as anxiety, abnormal thinking, confusion, depression, euphoria, and inability to concentrate.

Q: Does the efficacy of Dolorex diminish with repeated short-term use?

Studies on the drug’s pharmacokinetics indicate that steady state concentrations (consistent levels in the blood) are achieved after a few doses when administered every 6 hours.

Official data on short-term use observe that the maximum concentration remained consistent between the first day and the fifth day of treatment.

Q: Can breastfeeding mothers take Dolorex (Ketorolac)?

No. Ketorolac is contraindicated (prohibited) in breastfeeding mothers.

This is because the drug is known to pass into human milk, due to the potential exposure and associated risks to the nursing infant.

Q: What are the signs that Dolorex might be irritating the stomach?

Official warnings highlight the potential for serious gastrointestinal events, including bleeding and ulcers.

Serious gastrointestinal events may be indicated by symptoms such as bloody, black, or tarry stools, or coughing up blood or vomit that resembles coffee grounds.

Q: Does Dolorex (Ketorolac) have an impact on fertility?

Based on its mechanism of action—inhibiting prostaglandin synthesis—Ketorolac may impair female fertility.

For this reason, its use is not recommended in women who are actively attempting to conceive.

Q: Are there any known drug-drug interactions between Dolorex and common antidepressants?

Yes, co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs), a common class of antidepressants, is noted as an interaction risk.

This combination may increase the risk of gastrointestinal bleeding.

Q: What are the guidelines for stopping Dolorex after a short course of treatment?

Since the total duration of treatment is strictly limited to 5 days, the medicine should simply be discontinued upon completion of the course or when the acute pain no longer requires this level of analgesia.

There are no specific tapering guidelines needed for this short course of treatment.

Q: Can Dolorex be used as a pre-emptive painkiller before a procedure?

No. Regulatory documents state that Ketorolac is strictly contraindicated as a prophylactic analgesic (preventive painkiller) before any major surgery.

This is due to the potential for the drug to interfere with blood clotting.

Q: How does the body break down and eliminate Dolorex (Ketorolac)?

Ketorolac is primarily metabolized (broken down) in the liver into various inactive substances.

These metabolic products, along with some unchanged drug, are mostly eliminated from the body by the kidneys and excreted in the urine.

Q: What is the main reason Dolorex is considered an advanced pain management option?

Ketorolac is considered a potent analgesic indicated for moderately severe acute pain that requires analgesia at the opioid level.

Its availability in a rapid-acting intravenous/intramuscular form makes it a key non-opioid option in advanced hospital-based pain control.

How should Dolorex (Ketorolac) be stored and disposed of?

How to Store and Dispose of Dolorex (Ketorolac)?

Ketorolac tromethamine must be stored at Controlled Room Temperature, which is 20 to 25 C (68 to 77 F). The medication must be protected from light, excessive heat, moisture, and kept from freezing.

Storage and Protection

The product must be kept in the container it came in and kept tightly closed; the injectable solution should be retained in its carton until use. To ensure child safety, the medication must be stored out of the sight and reach of children and safety caps should always be locked.

Disposal Requirements

Any unused portion of the injection must be discarded immediately after use. For unused or expired tablets, dispose of the medicine according to local regulations. Ketorolac is not on the FDA flush list, and disposal should ideally utilize a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolorex (Ketorolac) found in:

A-Z Index: